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Introduction
The initial therapy for a clinically relevant stenosis in an 
arteriovenous fistula (AVF) is balloon angioplasty. A major 
concern is efficacy and longevity of the result after the 
treatment. Turmel-Rodrigues et al.1 reported the outcomes 
of interventional salvage of dysfunctional and thrombosed 
haemodialysis circuits. There were 220 cases in the dys-
functional AVF group. The 6-, 12- and 24-month primary 
patency (AVF working with no repeat intervention) 
reported were 67%, 51% and 37% for forearm AVF, and 
57%, 35% and 24% for upper arm AVF, respectively. More 
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Abstract
Introduction: Arteriovenous fistulas are the best form of vascular access for haemodialysis. A radiological balloon 
angioplasty is the standard treatment for a clinically relevant stenosis, but the recurrence rate is high. Data on factors 
associated with recurrence are limited.
Methods: A single centre, retrospective analysis was performed for 124 consecutive patients who had successful 
interventions for dysfunctional arteriovenous fistulae, to examine factors associated with post-intervention patency. 
Follow-up was at least 1 year for all patients. Variables associated with primary and cumulative patency were pre-
specified and assessed using both un-adjusted (univariate) and adjusted Cox proportional hazards models. Analysis was 
repeated for a subgroup of 80 patients with a single lesion only in order to examine the potential effects of stenotic 
lesion characteristics on patency.
Results: Factors found to have a significant association with poorer outcomes (less time to loss of patency) included 
thrombosis at the time of intervention and a history of previous intervention. Fistula age (log days) was significantly 
associated with better outcomes (greater time to loss of patency). Non-white ethnicity, lesion length, and patient age 
were also significantly associated with accelerated loss of patency.
Discussion: The factors we have identified as linked to poor outcome may help to identify patients in whom a balloon 
angioplasty is unlikely to provide a durable outcome. This may prompt exploring alternative treatment or dialysis options 
at an early stage.
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recently, Bountouris et al.2 reported the outcomes after 159 
percutaneous transluminal angioplasties (PTAs) in AVFs. 
Post-intervention primary patency (PIPP) at 6, 12 and 
24 months was 61%, 42% and 35%, respectively. Primary 
assisted patency (AVF working regardless of repeat inter-
vention) was 89% and 85% at 6 and 12 months, respec-
tively. Although there have been some exceptions,3,4 most 
other studies have reported similar primary patency rates 
of around 40%–50% at 1 year.5–7
There are limited data available regarding clinical fac-
tors predicting outcome after balloon angioplasty. 
Although the majority of potential factors are not modifi-
able, it remains important to understand how they affect 
outcome. If the outcome is unlikely to be successful, then 
the possibility of surgical revision or new access should be 
considered. These options all come with cost, inconven-
ience and discomfort. An estimate of the expected out-
come of a balloon angioplasty is therefore important 
information in determining the best course of action.
In this report, we describe a single centre experience of 
balloon angioplasty in 124 consecutive patients. In order 
to assess the effect of lesion anatomy, we also performed a 




We undertook a retrospective analysis of consecutive cases 
referred to interventional radiology, over an 18-month 
period between April 2013 and October 2014, with a dys-
functional AVF at our institution. We included for analysis 
the patients who had a technically successful interventional 
procedure: <30% residual stenosis in the access circuit. 
AVFs that had not been used for dialysis and AVFs throm-
bosed at the time of intervention were included. Balloon 
angioplasties were performed as follows. Prior to treat-
ment, 3000–5000 IU of heparin was administered. A Bard 
Conquest or Dorado high-pressure balloon was used as 
standard and was sized to the nominal vein diameter. It was 
inflated to ensure obliteration of the lesion waist with a 
minimum duration of balloon inflation of 1 min. If the radi-
ological result was suboptimal, further prolonged inflations 
of up to 5 min were performed and/or balloon diameter was 
upsized by 1–2 mm. Drug-coated balloons and cutting bal-
loons were not routinely used. Thrombosed AVFs were 
treated with pharmacomechanical thrombectomy with the 
Angiojet™ (Boston Scientific) device followed by balloon 
angioplasty of any significant stenosis. Each patient was 
considered only once, using the first intervention they 
underwent in the study period. The end of follow-up was 
1 year after the last procedure; therefore, all patients were 
followed up for at least 1 year. Tests were repeated twice for 
the two groups of patients: (1) all patients with one or more 
lesions (N = 124) and (2) subgroup of patients with one 
lesion only (N = 80). Data were obtained from a retrospec-
tive review of electronic patient records.
Definitions
Standardised definitions were used.8 PIPP ended when any 
of the following occurred: (a) access circuit thrombosis, (b) 
an intervention (either radiological or surgical) anywhere in 
the access circuit, or (c) the access circuit was abandoned 
due to an inability to treat any lesion. Post-intervention 
cumulative patency (PICP) was considered to end when the 
AVF was abandoned, regardless of radiological or surgical 
intervention, with or without a thrombosis event. Censoring 
occurred when the patient died or had a transplant before 
reaching the outcome(s). Both outcomes were calculated as 
time (days) between date of procedure and (a) end of 
patency, if the patient lost patency before end of follow-up; 
or (b) date of censor, if the patient had not lost patency 
before death or transplant; or (c) end of follow-up, if the 
patient has not lost patency before follow-up period. 
Variables to be assessed were identified a priori and all vari-
ables assessed are included in this report. In patients with 
one lesion only, the stenosis is classified as anastomotic if 
both vein and artery were affected, and juxtaanastamotic if 
they were within 3 cm of the anastomosis with the artery not 
affected. Central stenosis was defined as being central to the 
thoracic inlet.
Statistics
Descriptive statistics have been presented in n (%), mean 
(SD) or median (interquartile range (IQR)), as appropriate. 
For the inferential analysis, first, un-adjusted Cox propor-
tional hazard models were fitted separately for each of the 
patient characteristics in Table 1, to test which (if any) of 
the variables were univariately associated with either of 
the two outcomes within the two patient groups. Second, 
all relevant patient characteristics were then fitted into one 
adjusted model, per outcome, per group, to test whether 
any of the patient characteristics were significantly associ-
ated with the two outcomes when controlling for all other 
variables. Finally, stepwise estimation was performed 
using backward-selection, using α = 0.05 for removal from 
the Cox proportional hazards model: all relevant variables 
were included in an adjusted model and removed one by 
one if p < 0.05, leaving only significant covariates in the 
model. Graphical methods such as Kaplan–Meier survival 
curves were used to assess violations of the proportional 
hazards assumption, as well as Schoenfeld residuals. Log-
rank tests were also used to assess equality of survival 
functions for group variables in Figure 1.
Lesion site and lesion length were excluded from the 
first set of tests when including all patients (with one 
or more lesions) as they would be measurements of one 
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Table 1. Descriptive statistics of all patient variables regarded as potential predictors in the analysis.
Variable All patients (N = 124) Patients with one lesion only (N = 80)
Age (years)  
 Mean (SD) [range] 62.6 (15.1) [23, 90] 63.8 (16.0) [23, 90]
Age n (%)  
 <65 years 61 (49.2) 36 (45.0)
 ⩾65 years 63 (50.8) 44 (55.0)
Sex n (%)  
 Male 59 (47.6) 38 (47.5)
 Female 65 (52.4) 42 (52.5)
Ethnicity n (%)  
 Black 45 (36.3) 28 (35.0)
 Asian 12 (9.7) 7 (8.7)
 White 57 (46.0) 41 (51.3)
 Other 9 (7.3) 4 (5.0)
 Missing 1 (0.8)      –
Age of fistula (days)  
 Median (IQR) [range] 477.5 (211.5, 1243.5) [49, 4570] 472 (188, 1321) [49, 4570]
Statin therapy intensity† n (%)  
 None 60 (48.4) 37 (46.3)
 Low 5 (4.0) 4 (5.0)
 Medium 40 (32.3) 30 (37.5)
 High 19 (15.3) 9 (11.2)
History of coronary artery disease (CAD) n (%)  
 Yes 25 (20.2) 14 (17.5)
 No 99 (79.8) 66 (82.5)
History of peripheral vascular disease (PVD) n (%)  
 Yes 14 (11.3) 10 (12.5)
 No 110 (88.7) 70 (87.5)
Anticoagulation n (%)  
 Yes 7 (5.6) 3 (3.8)
 No 117 (94.4) 77 (96.2)
Diabetes n (%)  
 Yes 52 (41.9) 29 (36.3)
 No 72 (58.1) 51 (63.7)
Type of access n (%)  
 Brachiobasilic 43 (34.7) 28 (35.0)
 Brachiocephalic 70 (56.4) 44 (55.0)
 Radiocephalic 11 (8.9) 8 (10.0)
Lesion length (mm)
Mean (SD) [range]
     NA (n = 76)
3.8 (1.8) [1, 12]
Number of lesions n (%)  
 1 80 (64.5)  
 2 41 (33.1)  
 3 2 (1.6)  
 4 1 (0.8)      NA
Lesion site n (%)  
 Anastomotic 8 (10.0)
 Perianastamotic 14 (17.5)
 Mid-limb 27 (33.8)
 Swing point/cephalic arch 25 (31.2)
 Central stenosis 4 (5.0)
 Arterial      NA 2 (2.5)
Thrombosis n (%)  
 Yes 13 (10.5) 7 (8.7)
 No 111 (89.5) 73 (91.3)
Previous interventions n (%)  
 None 82 (66.1) 54 (67.5)
 1 30 (24.2) 19 (23.8)
 2 or more 12 (9.7) 7 (8.7)
IQR: interquartile range.
Low: Fluvastatin (20-–40 mg), Lovastatin (20 mg), Simvastatin (10 mg) or Pravastatin (10–20 mg); medium: Atorvastatin (10–20 mg), Fluvastatin (80 mg), Pravastatin 
(40–80 mg), Rosuvastatin (5–10 mg) or Simvastatin (20–40 mg); high: Atorvastatin (40–80 mg) or Rosuvastatin (20–40 mg).
†None: no statin therapy.
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Figure 1. (a) Kaplan–Meier survival function of time to post-intervention primary patency for patients with thrombosis compared 
to those without thrombosis, using the total sample of patients (one or more lesions). (b) Kaplan–Meier survival function of time to 
post-intervention cumulative patency for patients with thrombosis compared to those without thrombosis, using the total sample of 
patients (one or more lesions). Log-rank tests were statistically significant (p < 0.001) for both comparisons.
lesion only; similarly, number of lesions was not applica-
ble as a factor in the second set of tests when removing 
patients with multiple lesions. For some variables, multi-
ple categories were broadened or merged in order to cre-
ate binary variables. This was due to small numbers in 
sub-categories or to aid interpretation. Variables that 
were binarised were age (<65 years vs ⩾65 years), eth-
nicity (white vs non-white), statin therapy (none vs any), 
number of lesions (1 vs 2 or more), and previous inter-
vention (0 vs 1 or more). Age of fistula was log-trans-
formed to deal with the positive skewness of the variable, 
as well as the non-linear relationship between age of fis-
tula and the two outcomes. Software used was Stata ver-
sion 15.0 (StataCorp, Texas).
Results
Patient variables that we considered potentially associ-
ated with the outcomes are described in Table 1, and all 
characteristics appear to be similar between all patients 
(N = 124) and those with a single lesion only (N = 80). 
Table 2 shows descriptive data for the two patency 
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outcomes and the censor variables. Out of all 124 
patients, 6- and 12-month PIPP loss was 32.3% and 
44.4%, respectively. PICP loss for the 124 patients at 6 
and 12 months was 16.9% and 22.6%, respectively. For 
the 80 patients with a single lesion, PIPP loss at 6 and 
12 months was 31.3% and 43.8%, respectively. PICP 
loss for the 80 patients at 6 and 12 months was 13.8% 
and 20.0%, respectively.
Results of the Cox proportional hazards analyses for 
all 124 patients are shown in Table 3, reported as haz-
ard ratios (HR) and 95% confidence intervals (CI). 
Thrombosis at the time of presentation and younger fis-
tulas (log days) were significantly associated with 
worse outcomes (PIPP and PICP) in all three tests 
(adjusted and un-adjusted). Kaplan–Meier plots show-
ing the effect of thrombosis on PIPP and PICP are 
shown in Figure 1. Previous intervention and non-white 
ethnicity were also associated with both outcomes in 
the adjusted and stepwise models. Age of patient 
remained significant in the adjusted and stepwise mod-
els for time to PICP.
We performed a second analysis for patients with a sin-
gle lesion because it was not possible to assess the effect of 
lesion location and length if there were multiple lesions. It 
was impossible to study, for example, the effect of having 
a lesion at the anastomosis if there was an anastamotic 
lesion present, and a second lesion present in the venous 
segment and/or cephalic arch. Results of analyses for the 
80 patients with a single lesion only is shown in Table 4. 
Younger fistulas (log days) were significantly associated 
with both outcomes in the adjusted model. Statin use was 
associated with a shorter time to PICP in the unadjusted 
and stepwise models. Lesion length was significantly 
associated with time to PICP in the unadjusted, adjusted 
and stepwise models.
Discussion
In this study, we have found a significant association 
between poorer outcomes (less time to loss of patency) 
and thrombosis at the time of intervention or a history of 
previous intervention. Fistula age (log days) was signifi-
cantly associated with better outcomes (greater time to 
loss of patency). Non-white ethnicity, lesion length, and 
patient age were also significantly associated with accel-
erated loss of patency.
A publication in 2014 provides a systematic review of 
previous research.9 The authors identified 10 studies, which 
examined factors affecting primary patency after radiologi-
cal intervention.5–7,10–15 We have included two additional 
papers published since this review in our discussion.4,16 Our 
overall patency rates (Table 2) are consistent with previous 
reports. These studies have a number of limitations. 
Follow-up is variable and in some cases short. Six studies did 
not use multivariable methods in their analysis. No study 
was explicit about missing data. Most studies did not com-
ment on whether previous interventions had been performed. 
In some cases, the variables to be assessed were not pre-
specified, and variables found to be non-significant were not 
reported. Patients were sometimes included more than once 
in the study if they had a second fistula or intervention in the 
same fistula. Most studies were retrospective.
These previous studies have had a similar definition 
of PIPP. We considered that either surgical and radio-
logical endovascular intervention led to loss of primary 
patency, in keeping with standardised definitions.8 Our 
Table 2. Descriptive statistics of all outcome or censored variables by patency loss.
Variable All patients
N = 124
Patients with one lesion only
N = 80
PI primary patency 
loss
PI cumulative patency 
loss
PI primary patency loss PI cumulative patency 
loss
Censored within follow-up n (%)  
 Total 21 (16.9) 27 (21.8) 14 (17.5) 17 (21.3)
 Death 10 (8.1) 14 (11.3) 9 (11.3) 12 (15.0)
 Transplant 11 (8.9) 13 (10.5) 5 (6.2) 5 (6.3)
Overall loss of patency n (%)  
 Yes 66 (53.2) 36 (29.0) 40 (50.0) 20 (25.0)
 No 58 (46.8) 88 (71.0) 40 (50.0) 60 (75.0)
Loss of patency at… n (%)  
 6 months 40 (32.3) 21 (16.9) 25 (31.3) 11 (13.8)
 12 months 55 (44.4) 28 (22.6) 35 (43.8) 16 (20.0)
Time (days) to patency loss (n = 66) (n = 36) (n = 40) (n = 20)
Median (IQR) [range] 151 (89, 276) [2, 725] 148 (57, 291) [2, 777] 138.5 (89, 260.5) [10, 725] 136 (57, 291) [10, 558]
IQR: interquartile range.
The number of patients who were censored for death or transplant, and the number of patients who lost post-intervention (PI) primary patency 
and/or PI cumulative patency within the follow-up period.
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Table 3. Results of (a) un-adjusted Cox proportional hazards models to test univariate associations between patient characteristics 
and time to end (days) post-intervention (PI) patency loss of PI cumulative patency loss; (b) adjusted Cox proportional hazards 





(a) Un-adjusted Cox proportional 
hazards models
HR (95% CI)




















 <65 years (ref) – – – –  
 ⩾65 years 0.92 (0.57, 1.50) 1.38 (0.71, 2.66) 1.20 (0.66, 2.18) *2.31 (1.05, 5.08) NS *Sig.
Sex  
 Female (ref) – – – –  
 Male 1.17 (0.72, 1.90) 1.25 (0.65, 2.41) 1.10 (0.64, 1.90) 1.02 (0.48, 2.16) NS NS
Ethnicity  
 Non-white (ref) – – – –  
 White 0.66 (0.40, 1.08) 0.63 (0.32, 1.24) *0.46 (0.26, 0.83) *0.42 (0.18, 0.99) *Sig. *Sig.
Age of fistula (log 
days)
*0.80 (0.65, 0.99) *0.72 (0.53, 0.97) *0.67 (0.51, 0.88) *0.53 (0.35, 0.79) *Sig. *Sig.
Statins  
 None (ref) – – – –  
 Any 1.63 (1.00, 2.68) 1.76 (0.89, 3.47) 1.53 (0.80, 2.93) 0.88 (0.36, 2.15) NS NS
CAD  
 No (ref) – – – –  
 Yes 0.94 (0.52, 1.70) 1.25 (0.59, 2.66) 0.68 (0.32, 1.43) 1.11 (0.42, 2.89) NS NS
PVD  
 No (ref) – – – –  
 Yes 1.56 (0.77, 3.16) 1.83 (0.76, 4.43) 1.61 (0.70, 3.71) 1.09 (0.37, 3.18) NS NS
Anticoagulation  
 No (ref) – – – –  
 Yes 1.49 (0.60, 3.73) 1.41 (0.43, 4.62) 2.24 (0.79, 6.35) 2.30 (0.59, 9.00) NS NS
Diabetes –  
 No (ref) – – – –  
 Yes 1.18 (0.72, 1.92) 1.80 (0.94, 3.48) 0.86 (0.46, 1.62) 1.55 (0.61, 3.94) NS NS
Type of access  
 Brachiobasilic (ref) – – – – – –
 Brachiocephalic 0.93 (0.56, 1.56) 1.04 (0.52, 2.09) 1.05 (0.60, 1.85) 1.09 (0.49, 2.44)  
 Radiocephalic 1.13 (0.46, 2.77) 1.00 (0.28, 3.53) 1.46 (0.55, 3.85) 1.33 (0.33, 5.35) NS NS
Number of lesions  
 1 (ref) – – – –  
 2+ 1.19 (0.73, 1.95) 1.49 (0.77, 2.88) 1.20 (0.69, 2.08) 1.33 (0.63, 2.78) NS NS
Thrombosis  
 No (ref) – – – –  




 0 (ref) – – – –  
 1+ 1.09 (0.65, 1.81) 0.95 (0.47, 1.91) *2.12 (1.10, 4.06) *2.90 (1.18, 7.09) *Sig. *Sig.
HR: hazard ratio; CI: confidence interval; ref: reference category; Sig.: significant (p < 0.05) in stepwise regression; NS: not significant in stepwise 
regression and therefore removed from model; CAD: coronary artery disease; PVD: peripheral vascular disease.
*Statistically significant at the p < 0.05 level; **statistically significant at the p < 0.001 level.
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Table 4. Results of (a) un-adjusted Cox proportional hazards models to test univariate associations between patient characteristics 
and time to end (days) of post-intervention (PI) patency loss of PI cumulative patency loss, (b) adjusted Cox proportional hazards 
model controlling for all patient characteristics, and (c) stepwise estimation, for patients with one lesion only (N = 80).
Patient characteristics; 
potential predictors of 
the outcome(s)
(a) Un-adjusted Cox proportional 
hazards models
HR (95% CI)


















 <65 (ref) – – – –  
 ⩾65 0.79 (0.43, 1.47) 1.34 (0.55, 3.28) 0.75 (0.29, 1.89) 1.15 (0.27, 4.83) NS NS
Sex  
 Female (ref) – – – –  
 Male 1.19 (0.64, 2.22) 1.28 (0.53, 3.10) 1.84 (0.83, 4.06) 2.76 (0.70, 10.89) NS NS
Ethnicity  
 Non-white (ref) – – – –  
 White 0.73 (0.39, 1.37) 0.82 (0.34, 1.97) 0.60 (0.26, 1.39) 1.29 (0.35, 4.65) NS NS
Age of fistula (log days) 0.84 (0.66, 1.09) 0.74 (0.52, 1.06) *0.65 (0.44, 0.97) *0.48 (0.23, 0.99) NS NS
Statins  
 None (ref) – – – –  
 Any 1.59 (0.84, 2.99) *3.10 (1.13, 8.54) 2.34 (0.99, 5.53) 3.47 (0.73, 16.49) NS *Sig.
CAD  
 No (ref) – – – –  
 Yes 0.59 (0.23, 1.51) 1.25 (0.42, 3.75) 0.76 (0.22, 2.66) 5.49 (0.92, 32.64) NS NS
PVD  
 No (ref) – – – –  
 Yes 1.19 (0.47, 3.05) 1.45 (0.42, 4.97) 0.62 (0.12, 3.07) 0.67 (0.06, 7.91) NS NS
Anticoagulation  
 No (ref) – – – –  
 Yes 1.45 (0.35, 6.06) 1.46 (0.20, 11.00) 4.87 (0.31, 76.75) NA NS NS
Diabetes  
 No (ref) – – – –  
 Yes 1.04 (0.54, 2.02) 1.80 (0.74, 4.36) 1.29 (0.51, 3.26) 2.12 (0.45, 10.10) NS NS
Type of access  
 Brachiobasilic (ref) – – – –  
 Brachiocephalic 0.72 (0.37, 1.39) 0.66 (0.26, 1.67) 0.79 (0.32, 1.97) 0.49 (0.12, 1.92)  
 Radiocephalic 0.92 (0.31, 2.75) 0.73 (0.16, 3.37) 1.15 (0.28, 4.70) 0.89 (0.09, 8.64) NS NS
Lesion length (mm) 1.06 (0.90, 1.24) *1.21 (1.02, 1.43) 1.06 (0.81, 1.39) *1.89 (1.26, 2.84) NS *Sig.
Lesion site  
 Anastomotic (ref) – – – –  
 Perianast 1.01 (0.23, 4.55) 0.32 (0.03, 3.50) 3.37(0.43, 26.63) 0.29 (0.01, 8.21)  
 Mid-limb 1.50 (0.43, 5.18 0.89 (0.19, 4.31) 3.22 (0.54, 19.08) 0.34 (0.02, 4.71)  
 Swing point 1.42 (0.41, 4.97) 1.25 (0.27, 5.79) 3.85 (0.74, 20.08) 2.36 (0.25, 22.36)  
 Central stenosis 1.82 (0.37, 9.11) 0.91 (0.08, 10.03) 10.44 (1.18, 92.51) 4.78 (0.18, 125.04)  
 Arterial 0.69 (0.07, 6.80) NA NA NA NS NS
Thrombosis  
 No (ref) – – – –  
 Yes 1.96 (0.77, 5.03) 2.42 (0.71, 8.27) 2.32 (0.64, 8.42) 3.54 (0.55, 22.93) NS NS
Previous intervention  
 0 (ref) – – – –  
 1+ 1.06 (0.55, 2.05) −0.81 (0.31, 2.10) 1.29 (0.46, 3.61) 0.35 (0.06, 1.94) NS NS
HR: hazard ratio; CI: confidence interval; ref: reference category; Sig.: significant (p < 0.05) in stepwise regression; NS: not significant in stepwise 
regression and therefore removed from model; NA: not applicable due to small n; CAD: coronary artery disease; PVD: peripheral vascular disease.
*Statistically significant at the p < 0.05 level; **statistically significant at the p < 0.001 level.
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definition of PICP was not used in most. Instead, defini-
tions such as ‘assisted primary patency’ (time to throm-
bosis or surgical intervention) and ‘secondary patency’ 
(time to surgical intervention or abandoning of the AVF) 
were used. We consider that the endpoint of PICP is 
more clinically relevant than these. In our report, surgi-
cal revision (with the same AVF preserved) is compati-
ble with continued cumulative patency, in keeping with 
standardised definitions.8 From the perspective of both 
the patient and the clinical team, the important issue is 
how long their fistula lasts. A longer lasting fistula will 
also lead to reduced health care costs. If a fistula fails, 
then alternative and inferior access such as a central 
venous catheter or a synthetic graft, associated with 
higher morbidity, may be needed.
We found an effect of both previous intervention and 
thrombosis on both primary and cumulative patency in the 
total group of patients. It is not clear if the outcome would 
have been better if the thrombosis had been prevented. 
However, neither variable was significantly associated 
with outcome when restricting the cohort to patients with a 
single lesion only. We do not know if this reflects the 
smaller sample size or a true difference in the effect of 
previous intervention and thrombosis in patients with a 
single lesion. Thrombosis was assessed as a variable 
affecting primary patency in only two studies,6,12 with nei-
ther showing an effect.
We found that an older fistula had an improved pri-
mary and cumulative patency. Three of seven studies 
found that newer fistulas had a shorter primary 
patency,7,12,14 which is in keeping with this report. This 
reflects the fact that older fistulas are more mature. We 
did not collect data on how many of the fistulas had been 
used for dialysis prior to intervention. It is possible that a 
worse outcome would have been seen in fistulas that had 
not been used. Some of our patients had not yet started 
haemodialysis so a lack of use for dialysis would not nec-
essarily mean the fistula was not mature and suitable. It is 
not possible to comment on suitability for dialysis in a 
retrospective study, and this lack of assessment of fistula 
maturity is a limitation of our study.
We showed worse outcomes for non-white patients and 
for patients over 65 using both the adjusted and the step-
wise model. Ethnicity and age were not assessed in most 
previous studies. Overall, our data for other baseline clini-
cal and demographic variables are in keeping with previ-
ous studies, with the novel observation that ethnicity and 
age are relevant factors.
We found no effect for diabetes, previous peripheral 
vascular or coronary disease. Diabetes was associated with 
worse PIPP in two previous studies4,10 but not in eight oth-
ers. Two studies looked at peripheral vascular disease and 
coronary artery disease, and found no effect for either. 
None of the previous studies found an effect of the number 
of lesions, also in keeping with our data. Previous studies 
have not reported the effect of previous intervention on 
primary patency.
We found that longer lesions had a reduced cumula-
tive patency. Interpretation of previous published data 
on both lesion length and location is problematic. The 
current study is the only report we are aware of that 
describes the effect of lesion anatomy on outcome in 
patients with a single lesion. It is not clear how the pres-
ence of multiple lesions was accounted for and all series 
included a proportion of patients with more than one 
lesion. This may have obscured possible effects. Three 
studies found that longer lesions had a reduced 
PIPP,3,12,16 though lesion length had no effect in five 
other studies. One of these studies16 reported an effect 
of lesion location, suggesting that venous outflow pre-
dicted a worse outcome. In this study, 26% of patients 
had multiple lesions. Venous outflow lesions were 
stated as being present in 83%, but these were not sub-
divided into venous segment and cephalic arch making 
the findings difficult to interpret. Furthermore, only an 
unadjusted analysis was performed. Six other studies 
analysed the effect of lesion location with various dif-
ferent groups compared and no differences were found. 
In order to avoid the difficulties of interpreting the 
effect of lesion length and location with multiple 
lesions, we only assessed variables relating to lesion 
anatomy in 80 patients with a single lesion.
Our study is limited in that it is retrospective. However, 
it is one of the largest series reported, each patient is 
included only once, follow-up for all patients is at least 
1 year, variables of interest were specified prior to the anal-
ysis, and we have used multivariable methods in our anal-
ysis, allowing us to relate several risk factors, considered 
simultaneously, to patency survival time. Our data differ 
from prior reports in a number of ways. First, we have 
repeated our analysis in patients with a single lesion only 
to include the effect of lesion anatomy. Second, we have 
analysed the effect of ethnicity and previous intervention 
and found effects for both. The current data may inform 
decisions about repeat intervention and the timing of sur-
gery for new vascular access. In our experience, a young 
fistula, with previous interventions, and thrombosis at the 
time of presentation are a fistula that will not respond well 
to radiological intervention, in terms of patency outcomes. 
These findings may have been predicted by those with 
clinical experience. However, it is useful to have objective 
data to support these clinical impressions. In these patients, 
it may be wise to make plans for further access at the time 
of intervention or to consider not intervening at all. Further 
prospective data may soon be available from clinical trials 
assessing the effect of drug-coated balloons on balloon 
angioplasty, for example, the PAVE trial.17 In addition to 
assessing the study treatment, these trials will provide the 
opportunity to prospectively assess the effect of clinical 
variables on outcomes.
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